Publications by authors named "P R Kalra"
The ultimate goal of precision medicine is to tailor treatment to specific disease processes, thereby optimising patient outcomes. This approach moves beyond the one-size-fits-all model, recognising at an individual level the unique combinations of molecular, genetic, and environmental factors determining disease progression and treatment response. Chronic kidney disease (CKD) exemplifies the need for precision medicine, given its complex and heterogeneous nature.
View Article and Find Full Text PDFBackground: Non-anaemic iron deficiency is highly prevalent in people living with chronic kidney disease (CKD) but is underdiagnosed and undertreated, especially in earlier stages of CKD. A multicentre trial assessing the effect of intravenous iron supplementation in iron-deficiency but not anaemic people with CKD included a qualitative sub-study that aimed to explore the patient experience and psychosocial impact of living with CKD and iron deficiency, and the experience of the therapeutic intervention (intravenous iron and exercise).
Methods: Semi-structured interviews were conducted with 23 trial participants blinded to treatment.
Background: Inhalational anesthetic agents are a major source of potent greenhouse gases in the medical sector, and reducing their emissions is a readily addressable goal. Nitrous oxide (NO) has a long environmental half-life relative to carbon dioxide combined with a low clinical potency, leading to relatively large amounts of NO being stored in cryogenic tanks and H cylinders for use, increasing the chance of pollution through leaks. Building on previous findings, Stanford Health Care's (SHC's) NO emissions were analyzed at 2 campuses and targeted for waste reduction as a precursor to system-wide reductions.
View Article and Find Full Text PDFArticle Synopsis
- Fabry disease can lead to chronic kidney disease (CKD) due to accumulated sphingolipids causing kidney damage, impacting treatment and prognostic planning.
- In a study of 405 Fabry patients, significant findings included that 60.5% received treatments, 29.7% had cardiovascular events, and 3.3% reached end-stage kidney disease (ESKD), with men facing higher risks.
- Key indicators for CKD development included older age, history of cardiovascular issues, specific medication use, and higher urine albumin-to-creatinine ratios, highlighting the need for monitoring even in patients with normal kidney function.
Introduction: The Kidney BEAM randomized controlled trial reported clinically meaningful and statistically significant improvements in mental health-related quality of life (HRQoL), physical function (sit-to-stand-60, but not the physical component of HRQoL) and patient activation after a 12-week physical activity digital health intervention (DHI). This study explores factors that contributed to the effectiveness of Kidney BEAM through mixed methods analyses.
Methods: Quantitative data analysis was obtained from the recently published primary manuscript.